ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Sandu Pharmaceuticals appointed Dr. Neeti Madan Kapre as director and Dave & Dave as statutory auditor, while announcing other board and auditor tenure changes.
Sandu Pharmaceuticals has appointed M/s. Dave & Dave as Statutory Auditors for a five-year term, following the tenure expiry of the previous auditors.
Sandu Pharmaceuticals Limited held its 41st Annual General Meeting on September 11, 2026, via video conferencing to transact ordinary and special business items.
Sandu Pharmaceuticals Ltd issued a letter to shareholders whose email addresses are not registered, providing the weblink to the Annual Report for FY 2026-27.
Sandu Pharmaceuticals Limited has filed its 41st Annual Report for the financial year 2025-26, including the notice for the upcoming 41st Annual General Meeting.
Sandu Pharmaceuticals announced its 41st Annual General Meeting scheduled for September 11, 2026. The notice includes resolutions for dividend declaration and board appointments.
Sandu Pharmaceuticals Limited filed its quarterly Statement of Deviation or Variation in utilization of funds for the quarter ended June 30, 2026. No deviation or variation was reported.
Sandu Pharmaceuticals Ltd reported revenue from operations of ₹16.4 Cr (-1.8% YoY) and net profit of ₹0.2 Cr (+0.0% YoY) for Q1 FY27.
Sandu Pharmaceuticals scheduled a Board Meeting for August 11, 2026. The meeting will consider the standalone unaudited financial results for the quarter ended June 30, 2026.
Sandu Pharmaceuticals announced the demise of MD Shri Umesh B. Sandu. Consequently, Shri Balram Viswanathan was redesignated as Chairman and MD, and Dr. Neeti Kapre was appointed Independent Director.